Thiogenesis Therapeutics (TSXV:TTI) 3-Year EBITDA Growth Rate : -80.30% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics 3-Year EBITDA Growth Rate?

Thiogenesis Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was C$-0.02.

During the past 3 years, the average EBITDA Per Share Growth Rate was -80.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Thiogenesis Therapeutics was -38.70% per year. The lowest was -80.30% per year. And the median was -59.50% per year.

Competitive Comparison of Thiogenesis Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Thiogenesis Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's 3-Year EBITDA Growth Rate falls into.

Thiogenesis Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Thiogenesis Therapeutics (TSXV:TTI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Thiogenesis Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Thiogenesis Therapeutics (TSXV:TTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's lead compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live and side effects. TTI-0102's initial applications are for mitochondrial disease, Rett syndrome and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder